Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
about
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatitis B virus core protein with hot-spot mutations inhibit MxA gene transcription but has no effect on inhibition of virus replication by interferon αEfficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patientsPredictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisSerum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b.Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.The role of HBsAg quantification for monitoring natural history and treatment outcome.HBsAg quantification: useful for monitoring natural history and treatment outcome.Peginterferon α in the treatment of chronic hepatitis B.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.Virological and serological tools to optimize the management of patients with chronic hepatitis B.Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis.Loss of HBsAg and antiviral treatment: from basics to clinical significance.Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B.Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B.Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B.Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment.Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.The change of the quantitative HBsAg level during the natural course of chronic hepatitis B.Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNAQuantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir TreatmentStability of hepatitis B surface antigen over time: Implications for studies using stored sera
P2860
Q30391932-8A89EB7D-3DBF-4CA6-9F8D-185AC3F17A0AQ34273708-30BCC124-87D1-4061-961F-0CB3A8E87BCCQ37072918-D74F79C0-B028-49B9-8C8B-05B912A3BEA4Q37087279-F346C4B4-6834-43AF-B4CA-9E1475E9BF8EQ37102450-C8EC5302-4730-419F-A0C4-9FFA3FFD144CQ37762545-7E828E47-E3B3-4144-ABF2-8B5B38C4310DQ38071397-BCE4A893-8062-40AE-A98D-77182545A8FAQ38174257-E6C3379C-092C-4250-9E5D-7A4EB17D53B5Q38205028-838A9000-19E0-48BD-9F37-5F42836B2B76Q38295840-92727773-9197-4E3C-B495-21E761ABF012Q38601876-E6802253-6353-4FFC-A131-C7D22833B101Q38685589-3030978A-3B56-4923-8368-2AAE2D1659F9Q40335324-F158FD4B-BB82-4B7F-8B1B-6C13295AA5CDQ40493686-15554D3A-BC77-4248-A809-42A11ADE08A7Q41342289-84B28016-4AAA-4F88-9FE6-AEF9542497FAQ41718138-4C00D281-F1A7-41F8-8281-677527E8B157Q42227950-66D66185-147E-4A7D-B718-3D5195C6679EQ42235230-3BD51946-38DA-46BF-8A40-E81FCBF1F18AQ42265719-E72DFE61-4C97-4767-BCED-313B1670225EQ42333895-C37E30AA-BDE3-4B12-B0E6-4804AC061FF2Q45067577-A9001E49-28CA-46AF-991C-755DA49D0EC7Q45376971-589C0B2E-16A9-4415-8F76-449EFCDD1D57Q53425320-43A702A8-D415-4201-B1EE-4BCCB4F7EE61Q53898134-56381AFD-4306-4930-B038-80AC413381AEQ57491223-5DDA3B93-6AC2-4BBA-84EC-11726F60B3C9Q58235826-E6368B31-7820-441D-9B6F-CF7A53C8C6C7Q58235845-519F2320-59E4-43B7-8E66-FB0878D91BDE
P2860
Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@en
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@nl
type
label
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@en
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@nl
prefLabel
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@en
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@nl
P2093
P50
P1476
Low pretreatment serum HBsAg l ...... herapy in chronic hepatitis B.
@en
P2093
Pattaratida Sa-nguanmoo
Pisit Tangkijvanich
Varocha Mahachai
P304
P356
10.1016/J.JCV.2009.07.005
P577
2009-08-03T00:00:00Z